Skip to content
Home
About Us
Meet Invitrocue
Our Team
Partners
Corporate Governance
Careers
Oncology
Onco-PDO™
Patient FAQ
Physician FAQ
Preclinical Services
Overview
Drug Metabolism and Pharmacokinetics
Toxicology and Safety Assessment
Hepatocytes
3D Cell Culture
Customized Assays and Disease Modelling
Invivocue’s HiMice
Shareholders
Reports
Financial Reports
Analyst Reports
Announcements
Contact Management
News & Resources
Publications
Conferences & Events
Press Releases
Privacy Policy
Contact Us
English
English
Deutsch
Español
Português
中文 (中国)
中文 (香港)
Menu
Home
About Us
Meet Invitrocue
Our Team
Partners
Corporate Governance
Careers
Oncology
Onco-PDO™
Patient FAQ
Physician FAQ
Preclinical Services
Overview
Drug Metabolism and Pharmacokinetics
Toxicology and Safety Assessment
Hepatocytes
3D Cell Culture
Customized Assays and Disease Modelling
Invivocue’s HiMice
Shareholders
Reports
Financial Reports
Analyst Reports
Announcements
Contact Management
News & Resources
Publications
Conferences & Events
Press Releases
Privacy Policy
Contact Us
English
English
Deutsch
Español
Português
中文 (中国)
中文 (香港)
Analyst
Reports
Investors
Financial
Reports
Analyst
Reports
Press
Releases
ASX
Announcements
Investors
Financial Reports
Analyst Reports
Announcements
Shareholders
Biotech Daily May 2019 – Dr Boreham's Crucible
READ MORE >
June 13, 2019
Gordon Capital – October 2019 Research Updates
READ MORE >
February 13, 2019
NDF Research – 2019: Another year of progress expected for Onco-PDO
READ MORE >
February 7, 2019
Wise-Owl – December 2018 Updates
READ MORE >
December 19, 2018
Gordon Capital – October 2018 Research Updates
READ MORE >
November 9, 2018
Gordon Capital – October 2018 Research Updates
READ MORE >
October 27, 2018
Wise-Owl – Initiation of Coverage
READ MORE >
August 27, 2018
Gordon Capital – June Quarter 2018 Cash Flow Report
READ MORE >
August 24, 2018
NDF Research – Initiation of Coverage
READ MORE >
April 20, 2018
